Up next for KRAS: An advancing wave of G12D-targeting programs 

The next big precision-oncology race may be forming around KRAS G12D, a mutation with far greater prevalence and unmet need than G12C, but tougher chemistry. Structure-based drug design and new modalities are fueling a growing pipeline of candidates against the once-undruggable target.

In the last year alone, over 20 KRAS G12D-targeting programs have entered the clinic for solid tumors, expanding the G12D pipeline to three dozen candidates across seven modalities. One of the target’s biggest opportunities is also an indication in desperate need of treatment options: pancreatic cancer...